Who is the CEO of Cingulate Inc.?

The CEO of Cingulate Inc. is Shane J. Schaffer.

What industry does Cingulate Inc. belong to?

Cingulate Inc. operates in the Biotechnology industry within the Healthcare sector.

Where is Cingulate Inc. headquartered?

Cingulate Inc. is headquartered at 1901 West 47th Place, Kansas City, KS, 66205, US.

What is the IPO date of Cingulate Inc.?

Cingulate Inc. went public on December 8, 2021.

How many employees does Cingulate Inc. have?

Cingulate Inc. has approximately 13 full-time employees.

Cingulate Inc.

CING•NASDAQ

Healthcare

Biotechnology

$5.10

$-0.08(-1.54%)

Cingulate Inc. (CING) Company Profile & Overview

Explore Cingulate Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Cingulate Inc. (CING) Company Profile & Overview

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

SectorHealthcare

IndustryBiotechnology

CEOShane J. Schaffer

Contact Information

https://www.cingulate.com

913 942 2300

1901 West 47th Place, Kansas City, KS, 66205

Company Facts

13 Employees

IPO DateDec 8, 2021

CountryUS

Actively Trading

Frequently Asked Questions

;